Sugar industry sponsorship of germ-free rodent studies linking sucrose to hyperlipidemia and cancer

Sugar industry sponsorship of germ-free rodent studies linking sucrose to hyperlipidemia and cancer: An historical analysis of internal documents

This paper presents data that suggest that in 1970, the Sugar Research Foundation (SRF) withheld information from the public that the microbiome may be an important contributing factor to sucrose-induced hypertriglyceridemia and that sucrose consumption, compared to starch, might be associated with bladder cancer.

Abstract

In 1965, the Sugar Research Foundation (SRF) secretly funded a review in the New England Journal of Medicine that discounted evidence linking sucrose consumption to blood lipid levels and hence coronary heart disease (CHD). SRF subsequently funded animal research to evaluate sucrose’s CHD risks. The objective of this study was to examine the planning, funding, and internal evaluation of an SRF-funded research project titled “Project 259: Dietary Carbohydrate and Blood Lipids in Germ-Free Rats,” led by Dr. W.F.R. Pover at the University of Birmingham, Birmingham, United Kingdom, between 1967 and 1971. A narrative case study method was used to assess SRF Project 259 from 1967 to 1971 based on sugar industry internal documents. Project 259 found a statistically significant decrease in serum triglycerides in germ-free rats fed a high sugar diet compared to conventional rats fed a basic PRM diet (a pelleted diet containing cereal meals, soybean meals, whitefish meal, and dried yeast, fortified with a balanced vitamin supplement and trace element mixture). The results suggested to SRF that gut microbiota have a causal role in carbohydrate-induced hypertriglyceridemia. A study comparing conventional rats fed a high-sugar diet to those fed a high-starch diet suggested that sucrose consumption might be associated with elevated levels of beta-glucuronidase, an enzyme previously associated with bladder cancer in humans. SRF terminated Project 259 without publishing the results. The sugar industry did not disclose evidence of harm from animal studies that would have (1) strengthened the case that the CHD risk of sucrose is greater than starch and (2) caused sucrose to be scrutinized as a potential carcinogen. The influence of the gut microbiota in the differential effects of sucrose and starch on blood lipids, as well as the influence of carbohydrate quality on beta-glucuronidase and cancer activity, deserve further scrutiny.

Continue reading …

Examining metabolic therapy for brain cancer

Metabolic oncology is a relatively new area of cancer research and has the potential to offer new insights into cancer cells’ molecular flexibility, new biomarkers and even targeted therapies. “Metabolism” in this context refers to the metabolic activity inside cancer cells, not the rate at which the body processes energy from food.
Cancer cells are hungry. To feed their rapid growth and division, their metabolism changes. Moreover, they use sugar (glucose) in a different way to normal cells.

The animation below, created by Nature Reviews Drug Discovery, explores the key aspects of the altered metabolism in cancer cells and explains how these can be exploited for the development of new anticancer strategies.

Continue reading …

Translate »